Company Revenue

The company grew in the mid-single-digits during its fiscal 2025 on the strength of its differentiated enabling technology....

The company grew in the low double digits in 1Q25 on the strength of new product introductions and robust international...

The company grew in the mid-teens and could see even greater demand with MACI Arthro's use for trochlea defects....

The company's orthopedic sales declined about 10% in the first quarter of 2025, but its commercial channel showed ample promise....

The company grew in the low single digits for the first quarter of 2025 and expects accelerating growth through the...

The company faced market softness, supply issues and international order timing lumpiness as it declined in the low single digits....

The company's orthopedic sales grew 6% in the first quarter of 2025 on the strength of DUROLANE and Exogen....

The company grew nearly 25% in the first quarter of 2025 as its physician user base reached record levels....

The company grew in the low single digits for 1Q25 due to one less selling day and distributor team transitions....

The company grew in the low single digits in the first quarter of 2025 and it retools its U.S. sales...